MORGAN STANLEY PLC/CALL/INCYTE CO./65/0.5/20.12.24 | Market Closed - Börse Stuttgart 14:14:00 2024-05-17 EDT | ||
| 1.05 EUR | -9.48% |
|
| Current month | +34.62% | ||
| 1 month | +1.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 1.05 | -9.48% |
| 24-05-16 | 1.16 | +1.75% |
| 24-05-15 | 1.14 | -12.31% |
| 24-05-14 | 1.3 | -7.80% |
| 24-05-13 | 1.41 | +67.86% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 02:14 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME9H2Z |
| ISIN | DE000ME9H2Z8 |
| Date issued | 2024-03-01 |
| Strike | 65 $ |
| Maturity | 2024-12-20 (217 Days) |
| Parity | 2 : 1 |
| Emission price | 2.83 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.5 € |
|---|---|
| Lowest since issue | 0.69 € |
| Spread | 0.17 € |
| Spread % | 14.05% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
57.1
USD
Average target price
73.35
USD
Spread / Average Target
+28.46%
- Stock Market
- Warrants
- Warrant